Business
Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $11.7 million during the first quarter of 2025, a 38% increase over the prior year period. As a result the Company generated a net profit of $1.3 million for the quarter, adjusted earnings of $2.4 million, and cash flow from operations of $3.9 million.
About this update from Cumberland Pharmaceuticals Inc.
[{"type":"text","content":"NASHVILLE, Tenn., May 6, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $11.7 million during the first quarter of 2025, a 38% increase over the prior year period. As a result the Company generated a net profit of $1.3 million for the quarter, adjusted earnings of $2.4 million, and cash flow from operations of $3.9 million.","length":483,"tagName":"p"},{"type":"image","alt":"Cumberland Pharmaceuticals Logo (PRNewsFoto/Cumberland Pharmaceuticals Inc.)","displaySize":"","headline":null,"caption":"Cumberland Pharmaceuticals Logo (PRNewsFoto/Cumberland Pharmaceuticals Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":85,"url":"https://media.zenfs.com/en/prnewswire.com/3afebe83ec3d4bc266a4bcc9278af913"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/W65H8Am_Z_mSA2sDK0ostg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3afebe83ec3d4bc266a4bcc9278af913","width":400,"height":85}},"href":"https://mma.prnewswire.com/media/84325/Cumberland_Pharmaceuticals_logo_new1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Cumberland ended the quarter with approximately $70 million in total assets, $41.6 million in liabilities and $28.7 million of shareholders' equity.","length":152,"tagName":"p"},{"type":"text","content":""We are entering an exciting time for our company, as we continue to build momentum and capitalize on a range of promising opportunities," said Cumberland Pharmaceuticals CEO A.J. Kazimi. "Our optimism is driven by strong performance from our approved brands, the expansion of international partnerships, meaningful progress across our clinical development programs and the potential for strategic acquisitions."","length":432,"tagName":"p"},{"type":"text","content":"RECENT COMPANY DEVELOPMENTS INCLUDE:","length":36,"tagName":"p"},{"type":"text","content":"Top-Line DMD Study Results","length":26,"tagName":"p"},{"type":"text","content":"In February 2025, Cumberland announced positive top-line results from the Phase II study evaluating its ifetroban product candidate in patients with Duchenne muscular dystrophy (DMD). This marks a breakthrough for...